Health Trials

Microvascular Cardiac Allograft Vasculopathy Trial

ConditionCardiac Allograft Vasculopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGerman Heart Institute

About this trial

The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).

The utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).

Eligibility criteria

Qualifiers

able to consent

Written consent of the participant after clarification and sufficient time to think about participation

heart transplant recipient

Indication for routine invasive diagnostics or due to symptoms

Disqualifiers

Addiction or other diseases that do not allow the patient to assess the nature and scope as well as possible consequences of the study

Patients or their legal guardians who do not sign the declaration of consent or who cannot fully understand it due to a lack of German language skills

Pregnant women, breastfeeding women

Severe comorbidities affecting the miRNA profile: diabetes mellitus, malignancy, end-stage renal disease with renal replacement therapy

Trial design

Treatments tested in this trial

  • Echocardiography
  • Magnetic resonance imaging
  • Magnetocardiography
  • Histology
  • Genetics
  • calcium signaling
  • IMR
  • Angio-IMR

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

German Heart Institute

Lead sponsor

Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Collaborator

Deutsche Stiftung für Herzforschung

Collaborator

Source ClinicalTrials.gov